Zacks Small Cap Has Bearish Forecast for DWTX Q2 Earnings

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) – Analysts at Zacks Small Cap lowered their Q2 2025 earnings estimates for Dogwood Therapeutics in a research note issued on Tuesday, May 13th. Zacks Small Cap analyst D. Bautz now forecasts that the company will post earnings of ($2.00) per share for the quarter, down from their previous forecast of ($1.00). The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. Zacks Small Cap also issued estimates for Dogwood Therapeutics’ Q3 2025 earnings at ($2.00) EPS, Q4 2025 earnings at ($2.00) EPS, FY2025 earnings at ($8.66) EPS, FY2026 earnings at ($5.67) EPS and FY2027 earnings at ($4.45) EPS.

Separately, HC Wainwright upgraded shares of Dogwood Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Wednesday, April 23rd.

Dogwood Therapeutics Price Performance

Shares of Dogwood Therapeutics stock opened at $5.32 on Friday. Dogwood Therapeutics has a 1 year low of $1.62 and a 1 year high of $29.28. The firm has a market cap of $10.17 million, a PE ratio of -0.81 and a beta of 1.98. The company has a 50 day simple moving average of $5.08 and a two-hundred day simple moving average of $4.93.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its earnings results on Thursday, May 8th. The company reported ($4.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($3.44).

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Dogwood Therapeutics stock. FNY Investment Advisers LLC purchased a new position in shares of Dogwood Therapeutics, Inc. (NASDAQ:DWTX) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,500 shares of the company’s stock, valued at approximately $62,000. FNY Investment Advisers LLC owned approximately 0.65% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.